Eli Lilly Zepbound Price Cut Widens Access
Eli Lilly Zepbound Price Cut on LillyDirect lowers cash costs for U.S. patients, echoes Novo moves and the White House deal and nudged shares lower.
KEY TAKEAWAYS
- Lilly cut LillyDirect introductory vial prices to $299, $399 and $499 per month to broaden access.
- Move follows Novo Nordisk cash-pay discounts and a White House pricing deal shaping future pen and Medicare cuts.
- Shares had fallen to $1,066.96 at the time of reporting.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Eli Lilly lowered introductory cash prices for Zepbound on its LillyDirect portal, effective Dec. 1, 2025, aiming to expand access after rival discounts and a White House pricing agreement.
LillyDirect Price Cuts
Lilly set the lowest-dose Zepbound vial at $299 per month, down from about $349, and the next tier at $399, reduced from roughly $499. The highest-dose vials remain priced at $499 per month. These discounts apply to cash-paying patients with valid prescriptions and mark Lilly's second price cut for Zepbound vials on LillyDirect this year. Ilya Yuffa, president of Lilly USA, said the company will continue expanding delivery options and access pathways to reach more patients.
Competition and Policy Context
The price cuts follow Novo Nordisk’s November reduction of cash-pay introductory prices for Ozempic and Wegovy to $199 for the first two months, then $349 monthly. Lilly and Novo Nordisk compete through pharmacy-benefit-manager deals, cash-pay discounts, and direct employer arrangements as the global obesity-drug market approaches $100 billion by 2030.
A White House-negotiated agreement calls for a 71% Medicare discount on Ozempic and Wegovy starting in 2027. Under that deal, Lilly committed to reduce Zepbound multidose-pen prices beginning in 2026.
Lilly shares fell about 0.9% to $1,066.96 following the announcement.
